M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.375, pp.1823-1833, 2016.

M. Reck, Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer, Immunotherapy, vol.10, pp.2234-2246, 2018.

T. S. Mok, Y. Wu, I. Kudaba, D. M. Kowalski, B. C. Cho et al., Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial, Lancet, vol.393, pp.1819-1830, 2019.

T. S. Mok, Y. Wu, I. Kudaba, D. M. Kowalski, B. C. Cho et al., Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC, Ann. Oncol, vol.2019

R. Hui, E. B. Garon, J. W. Goldman, N. B. Leighl, M. D. Hellmann et al., Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: A phase 1 trial, Ann. Oncol, vol.28, pp.874-881, 2017.

E. J. Aguilar, B. Ricciuti, J. F. Gainor, K. L. Kehl, S. Kravets et al., Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression, Ann. Oncol, vol.30, pp.1653-1659, 2019.

S. Peters, M. Reck, E. F. Smit, T. Mok, and M. D. Hellmann, How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer, Ann. Oncol, vol.30, pp.884-896, 2019.

Y. Yu, D. Zeng, Q. Ou, S. Liu, A. Li et al., Association of Survival and Immune-Related Biomarkers with Immunotherapy in Patients with Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis, JAMA Netw

D. Lardinois, W. Weder, T. F. Hany, E. M. Kamel, S. Korom et al., Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography, N. Engl. J. Med, vol.348, pp.2500-2507, 2003.

B. Fischer, U. Lassen, J. Mortensen, S. Larsen, A. Loft et al., Preoperative staging of lung cancer with combined PET-CT, N. Engl. J. Med, vol.361, pp.32-39, 2009.

L. Goldfarb, B. Duchemann, K. Chouahnia, L. Zelek, and M. Soussan, Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: Introduction of iPERCIST, EJNMMI Res, vol.9, issue.8, 2019.

J. Vansteenkiste, B. M. Fischer, C. Dooms, and J. Mortensen, Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: Systematic review, Lancet Oncol, vol.5, pp.531-540, 2004.

C. J. Hoekstra, S. G. Stroobants, E. F. Smit, J. Vansteenkiste, H. Van-tinteren et al., Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer, J. Clin. Oncol, vol.23, pp.8362-8370, 2005.

C. Pöttgen, S. Levegrün, D. Theegarten, S. Marnitz, S. Grehl et al., Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy, Clin. Cancer Res, vol.12, pp.97-106, 2006.

J. Tanizaki, K. Haratani, H. Hayashi, Y. Chiba, Y. Nakamura et al., Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab, J. Thorac. Oncol, vol.13, pp.97-105, 2018.

A. Prelaj, R. Tay, R. Ferrara, N. Chaput, B. Besse et al., Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer, Eur. J. Cancer, vol.106, pp.144-159, 2019.

R. Seban, C. Robert, L. Dercle, R. Yeh, A. Dunant et al., Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy

G. Polverari, F. Ceci, V. Bertaglia, M. L. Reale, O. Rampado et al., 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival, Cancers, vol.12, 1163.

R. Seban, L. Mezquita, A. Berenbaum, L. Dercle, A. Botticella et al., Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors, Eur. J. Nucl. Med. Mol. Imaging, vol.47, pp.1147-1157, 2020.

L. L. Munn, Cancer and inflammation, Wiley Interdiscip Rev. Syst. Biol. Med, vol.9, 1370.

P. F. Ferrucci, P. A. Ascierto, J. Pigozzo, M. Del-vecchio, M. Maio et al., Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab, Ann. Oncol, vol.27, pp.732-738, 2016.

M. Capone, D. Giannarelli, D. Mallardo, G. Madonna, L. Festino et al., Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab, J. Immunother. Cancer, vol.6, 2018.

D. E. Meyers, I. Stukalin, I. A. Vallerand, R. T. Lewinson, A. Suo et al., The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors, Cancers, vol.11, 1713.

L. Mezquita, E. Auclin, R. Ferrara, M. Charrier, J. Remon et al., Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non-Small Cell Lung Cancer, JAMA Oncol, vol.4, pp.351-357, 2018.

J. Ruiz-bañobre, M. C. Areses-manrique, J. Mosquera-martínez, A. Cortegoso, F. J. Afonso-afonso et al., Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy, Transl. Lung Cancer Res, vol.8, pp.1078-1085, 2019.

R. Seban, J. S. Nemer, A. Marabelle, R. Yeh, E. Deutsch et al., Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: Association with outcome and transcriptomics, Eur. J. Nucl. Med. Mol. Imaging, vol.46, pp.2298-2310, 2019.

R. Seban, A. Moya-plana, L. Antonios, R. Yeh, A. Marabelle et al., Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4, Eur. J. Nucl. Med. Mol. Imaging, vol.47, pp.2301-2312, 2020.

A. Castello, L. Toschi, S. Rossi, E. Mazziotti, and E. Lopci, The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors, J. Cancer Res. Clin. Oncol, vol.146, pp.1235-1243, 2020.

D. Volterrani, G. Daniele, S. Mazzarri, F. Guidoccio, A. Dardano et al., Annual Congress of the European Association of Nuclear Medicine, Eur. J. Nucl. Med. Mol. Imaging, vol.46, pp.1-952, 2019.

S. E. Bleeker, H. A. Moll, E. W. Steyerberg, A. R. Donders, G. Derksen-lubsen et al., External validation is necessary in prediction research: A clinical example, J. Clin. Epidemiol, vol.56, pp.826-832, 2003.

R. Zahorec, Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill, Bratisl. Lek. Listy, vol.102, pp.5-14, 2001.

A. Castello, S. Rossi, L. Toschi, E. Mazziotti, and E. Lopci, Hyper-progressive Disease in Patients With Non-Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of 18F-FDG PET/CT, J. Nucl. Med, vol.61, pp.821-826, 2019.

R. Seban, L. H. Schwartz, G. Bonardel, and L. Dercle, Diagnosis of Hyper-progressive Disease in Patients Treated with Checkpoint Inhibitors using 18F-FDG PET/CT, J. Nucl. Med, 2020.

L. Gandhi, D. Rodríguez-abreu, S. Gadgeel, E. Esteban, E. Felip et al., Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N. Engl. J. Med, vol.378, pp.2078-2092, 2018.

Y. Zhou, C. Chen, X. Zhang, S. Fu, C. Xue et al., Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: A systematic review and meta-analysis, J. Immunother. Cancer, vol.6, p.155, 2018.

J. C. Benitez, G. Recondo, E. Rassy, and L. Mezquita, The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors, Q. J. Nucl. Med. Mol. Imaging, vol.64, pp.162-174, 2020.

L. Seymour, J. Bogaerts, A. Perrone, R. Ford, L. H. Schwartz et al., Guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol, vol.18, pp.143-152, 2017.

?. Houdek, T. Büchler, and E. Kindlová, Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours, Klin. Onkol, vol.30, pp.32-39, 2017.

R. Boellaard, R. Delgado-bolton, W. J. Oyen, F. Giammarile, K. Tatsch et al., FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0, Eur. J. Nucl. Med. Mol. Imaging, vol.42, pp.328-354, 2015.

K. Ito, H. Schöder, R. Teng, J. L. Humm, A. Ni et al., Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy, Eur. J. Nucl. Med. Mol. Imaging, vol.46, pp.930-939, 2019.